icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
Merck at AASLD / HepDart 2015
 
 
  AASLD: Summary from AASLD 2015 for Hepatitis C Beyond 95% SVR cure rates: still room for improvement? Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany
 
-------------------------
 
Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection - (07/31/15) - PDUFA Jan 28 2016
 
AASLD: Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting® - (11/19/15)
 
AASLD: Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting® - (11/18/15)
 
AASLD: Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy - (11/18/15)
 
--------------------------
 
AASLD: The Combination of Elbasvir and Grazoprevir ▒ RBV Is Highly Effective for the Treatment of GT1a-Infected Patients - (11/17/15)
 
hepDART: Optimizing Outcomes in HCV Patients: Elbasvir/Grazoprevir: kidney disease/IDUs/resistance (01/04/16)
 
AASLD: AN INTEGRATED ANALYSIS OF 402 COMPENSATED CIRRHOTIC PATIENTS WITH HCV GENOTYPE (GT) 1, 4 or 6 INFECTION TREATED WITH Elbasvir/GRAZOPREVIR - (11/19/15)
 
AASLD: Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks - (11/23/15)
 
AASLD: C-SWIFT Retreatment (Part B): 12 Weeks of Elbasvir/Grazoprevir with Sofosbuvir and Ribavirin Successfully Treated G1-Infected Subjects who Failed Short-Duration All-Oral Therapy - (11/23/15)
 
AASLD: C-EDGE CO-STAR: efficacy of grazoprevir / elbasvir Fixed Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy - (11/16/15)
 
AASLD: C-EDGE Co-Infected: final results from Phase 3 Study of elbasvir / grazoprevir in Patients with HCV/HIV - (11/30/15)
 
AASLD: Eliminate Restrictions to Substance Users/Injection Drug Users - SVR Rates the Same in New Study as in Non-IDUs 96% - Routine HCV Testing is needed - (11/18/15)
 
AASLD: No Pharmacokinetic Interaction Between HCV NS5A Inhibitor Elbasvir and Buprenorphine/Naloxone in Healthy Volunteers - (11/18/15)
 
hepDART: (HepDart) PREVALENCE AND IMPACT OF BASELINE NS5A RESISTANCE ASSOCIATED VARIANTS (RAVS) IN HCV GT1A PATIENTS TREATED WITH ELBASVIR/GRAZOPREVIR (EBR/GZR) (12/22/15)
 
AASLD: Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 1nfection (Part A of C-CREST-1 & 2) - (11/23/15)
 
hepDART: Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 Infection (Part A of C-CREST 1 & 2) (12/14/15)
 
AASLD: Predictors of Response to Elbasvir/Grazoprevir Among HCV Genotype 1 (GT1)-Infected Patients: Integrated Analysis of Phase 2-3 Trials -2 - (01/08/16)
 
AASLD: Safety and Tolerability of Elbasvir/Grazoprevir in Patients With Chronic Hepatitis C: An Integrated Analysis of Phase 2-3 Trials - (01/04/16)
 
AASLD: High Efficacy of the Combination HCV Regimen Elbasvir and Grazoprevir for 8 or 12 Weeks With or Without Ribavirin in Treatment-Naive, Non-Cirrhotic HCV GT1b-Infected Patients: An Integrated Analysis - (01/04/16)
 
AASLD: Efficacy, Safety and Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Hepatitis C Genotype 1 Infected Non-cirrhotic Japanese Patients (Phase 2 Portion in Phase 2/3 Combined Study) - (01/04/16)
 
AASLD: Efficacy of Elbasvir (EBR) and Grazoprevir (GZR) in Black HCV-Infected Patients: Results of a Pooled Analysis of Phase 2/3 Studies - (12/03/15)
 
AASLD: High Efficacy of Elbasvir and grazoprevir With or Without Ribavirin in 103 Treatment-Naive and Experienced Patients With HCV Genotype 4 Infection: A Pooled Analysis - (12/01/15)
 
-------------------------------
 
AASLD: C-EDGE TN: Impact of 12-Week Oral Regimen of Elbasvir (EBR, MK-8742) / Grazoprevir (GZR, MK-5172) on Patient-Reported Outcomes (PROs) in Treatment-Na´ve Patients With Chronic Hepatitis C Virus (HCV) Genotype (GT) 1, 4, or 6 Infection - (01/04/16)
 
AASLD: C-EDGE Co-infection: Impact of 12-Week Oral Regimen of Elbasvir (EBR, MK-8742)/Grazoprevir (GZR, MK-5172) on Patient-Reported Outcomes (PROs) in Treatment- Na´ve Patients With HCV/HIV Co-infection - (01/04/16)
 
----------------------------------
 
AASLD: Projected Long-term Impact of Grazoprevir (GZR, MK-5172)/Elbasvir (EBR, MK-8742) in Treatment-na´ve and Treatment-experienced Patients With Hepatitis C Virus Genotype 1 Infection and Chronic Kidney Disease - (12/16/15)
 
EASL: C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE - (04/23/15)
 
AASLD: Hepatitis C and Renal Disease: Differences in Patient Characteristics and Clinical Outcomes in the United States - (12/16/15)
 
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial - (01/06/15) published
 
More Hep C Articles...